Key facts
- This page summarizes Jerman Michael A.'s Form 4 filing for Telomir Pharmaceuticals, Inc. (TELO).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 29 Aug 2024, 16:05.
Jerman Michael A. - 27 Aug 2024 Form 4 Insider Report for Telomir Pharmaceuticals, Inc. (TELO)
- Reporting relationship
- Director
- Issuer ticker
- TELO
- Reported as of
- 27 Aug 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 29 Aug 2024, 16:05:20 UTC
- Prior SEC filing
- 16 May 2024
- Next SEC filing
- 17 Jul 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Jerman
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jerman Michael A. filed Form 4 for Telomir Pharmaceuticals, Inc. (TELO) on 29 Aug 2024.
Change
- Previous filing in this sequence was filed on 16 May 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TELO
transaction
Derivative
Incentive Stock Options (right to buy)
Award
- Transaction value
- $0
- Shares
- +25,000
- Change %
- Price
- $0.000000
- Shares after
- 25,000
- Date
- 27 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $5.02
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on August 26, 2024.
Footnote F2
The stock options were issued to the Reporting Person on August 26, 2024, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). Fifty percent of the stock options vested immediately upon issuance and the remaining fifty percent of the stock options are to vest on February 26, 2025.